Overview

Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe atopic dermatitis
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Celgene Corporation
Treatments:
Apremilast
Thalidomide